HSPH1 and colorectal carcinoma: Immunotherapy targeting MAGE has achieved ideal results in treatment of metastatic CRC, and entered phase II clinical trial [48, 49]; the polypeptide vaccine based on HSP105 (heat shock protein family h member 1) induced strong immune response and was used to treat advanced CRC [50].